Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-839 in Relapsed/Refractory Leukemia
NCT02071927Phase 1Completed
- Sponsor
- Calithera Biosciences
- Start
- Mar 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of telaglenastat in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Calithera Biosciences. Primary endpoint: Incidence of adverse events. Started Mar 2014; status: completed.
02
Drugs
telaglenastat
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02071927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071927.